NCT00080340 is a Phase 3 clinical trial of TLK286 (Telcyta) HCl for Injection in Non Small Cell Lung Carcinoma, sponsored by Telik.

Who is sponsoring NCT00080340?

NCT00080340 is sponsored by Telik.

What drugs are being tested in NCT00080340?

Interventions in NCT00080340: TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa).

What condition does NCT00080340 study?

NCT00080340 studies Non Small Cell Lung Carcinoma.

Is NCT00080340 still recruiting?

NCT00080340 is currently completed. Last updated 10 January 2008.

Last reviewed 2008-01-10 · How we verify

NCT00080340

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed Phase 3 Last updated 10 January 2008

What this trial tests

Phase 3 trial testing TLK286 (Telcyta) HCl for Injection in Non Small Cell Lung Carcinoma in 520 participants. Completed in 1 May 2005.

Timeline

1 May 2005

Quick facts

Lead sponsor	Telik
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	520
Estimated completion	1 May 2005
Sites	338 locations across United States, Argentina, Australia, Brazil, Chile, Germany, Italy, United Kingdom

Drugs / interventions tested

TLK286 (Telcyta) HCl for Injection — full drug profile →
gefitinib (Iressa) — full drug profile →

Conditions studied

Non Small Cell Lung Carcinoma — all drugs for Non Small Cell Lung Carcinoma →

Sponsor

Telik — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00080340 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Telik
Last refreshed: 10 January 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00080340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing